Navigation Links
New Scientific Studies Show Further Evidence of Avandia Dangers
Date:2/4/2010

Two independent studies document serious medical risks associated with use of popular GlaxoSmithKline diabetes drug

Mineola, NY (Lexis Nexis) February 4, 2010 -- Pharmaceutical giant GlaxoSmithKline is about to suffer more setbacks in the ongoing battle of opinions concerning the safety of its much touted diabetes drug Avandia, according to Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y.

The American Diabetes Association has accepted for publication in its prestigious medical journal, Diabetes Care, a study by Harvard researchers that shows users of the diabetes drug Avandia have more than double the risk of a heart attack compared to other diabetes drugs. Further, a jointly sponsored study by both GlaxoSmithKline and i3 Drug Safety, an independent drug-safety firm, will appear in the journal Clinical Therapeutics, showing that Avandia users have a 35-41% increased risk of a heart attack over users of Actos©, Avandia's main competitor.

These findings are the latest in a series of published studies that indicate Avandia users are at an unacceptably increased risk of a heart attack. In 2007, the Food and Drug Administration required a "Black Box" warning be added to Avandia's label about the heart risks associated with drug, but allowed the product to remain on the market even though numerous Endocrinologists and other diabetes experts called for its removal from the market like the other ill-fated drugs Vioxx and Rezulin.

The Harvard group analyzed clinical care data taken from the electronic medical records of patients at several Boston area hospitals and clinics associated with Harvard Medical School. All 26,375 patients records reviewed included a diagnosis of Diabetes and the use of at least one oral diabetic medication used between years 2000 and 2006. The researchers then reviewed the records for all patients who suffered "Myocardial Infarction" or heart attack. The incidence of heart attack was more than double for Avandia compared to its competitor Actos. The researchers chose Avandia to confirm their methodology because of its known "…relative adverse cardiovascular risk profile…" The GlaxoSmithKline-i3 study analyzed health-insurance data from July of 2000 through March of 2007 for 2 groups of 47,501 subjects each; one group using Avandia and the other Actos.

Almost 13,000 former Avandia users who have suffered heart attacks and other significant injuries have filed claims against GlaxoSmithKline in both Federal and State courts.

"This study adds to the overwhelming evidence that Avandia causes heart attacks in an already vulnerable population and it further confirms the basis of these lawsuits," said Marc Grossman, a New York attorney who represents hundreds of former Avandia users in Federal Court in Philadelphia. "It's very disturbing to see what appears to be a pattern of pharmaceutical corporations placing profits ahead of people. The recent studies raise serious questions about the health risks associated with Avandia, yet GSK continues to shirk its responsibility to the thousands of victims of Avandia whose lives are ruined or lost."

The Sanders Firm is a National Law Firm and has recovered over $500 Million for its clients, including thousands of victims of defective drugs and products. For further information or press inquiries, please contact Marc Grossman at 1-800-FAIR-PLAY, via email at mgrossman(at)thesandersfirm(dot)com or go to www.thesandersfirm.com.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3563424.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009
2. The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
3. American Scientific Resources 2009 Annual Meeting of Shareholders Adjourned
4. American Scientific CE Removed - Now Current Information
5. Lung Cancer Foundation of America Gives the Gift of Life This Holiday Season: Announces Inaugural $125,000 Scientific Research Grant
6. Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases
7. Scientific panel evaluates soy infant formula safety
8. The Concord Grape Commands Attention at Major Scientific Conference
9. Patriot Scientific Corporation Announces New Director
10. Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
11. Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientifics PureWeb Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology: